Pharmacokinetic Profile of a Low-Molecular Weight Heparin (Reviparin) in Pregnant Patients: A Prospective Cohort Study
详细信息    查看全文
文摘
Anticoagulant therapy during pregnancy is problematic. Patients are frequently treated with long-term low-molecular weight heparin despite a lack of evidence for its effectiveness, and in the absence of validated dosing recommendations. The objectives of this investigation were to characterize the safety and pharmacokinetic behavior of a low-molecular weight heparin (reviparin) administered throughout pregnancy. Forty-two patients followed in a tertiary-care rheumatology clinic who received prophylactic doses of reviparin (4900 anti-Xa units subcutaneously once daily) were enrolled in this investigation. Anti-Xa heparin levels, weights, and gestational ages of the patients were obtained on up to four occasions distributed throughout their pregnancy. The achieved anti-Xa heparin levels were highly correlated with the patient's weight, irrespective of the gestational age. No toxicity other than injection site hematomas was observed. The achieved intensity of anticoagulation with reviparin varies during pregnancy in direct proportion to the patient's weight. This variability may mandate dose adjustment in response to changes in a patient's weight during pregnancy, particularly if low-molecular weight heparin is administered at therapeutic doses. font> <font face=""arial"" size=""-1"" color=""black""> Publisher: font> <font face=""arial"" size=""-1"" color=""black""> Elsevier Science font> <font face=""arial"" size=""-1"" color=""black""> Language of Publication: font> <font face=""arial"" size=""-1"" color=""black""> English font> <font face=""arial"" size=""-1"" color=""black""> Item Identifier: font> <font face=""arial"" size=""-1"" color=""black""> S0049-3848(99)00228-5 font> <font face=""arial"" size=""-1"" color=""black""> Publication Type: font> <font face=""arial"" size=""-1"" color=""black""> Article font> <font face=""arial"" size=""-1"" color=""black""> ISSN: font> <font face=""arial"" size=""-1"" color=""black""> 0049-3848 font> <font face=""arial"" size=""-1"" color=""black""> Cited by: font> <font face=""arial"" size=""-1"" color=""black"">
  1. Eldor, Amiram,""The use of low-molecular-weight heparin for the management of venous thromboembolism in pregnancy""European Journal of Obstetrics and Gynecology and Reproductive Biology2002pp. 3-13
    f=""http://202.120.13.78/cgi-bin/sciserv.pl?collection=journals&journal=03012115&issue=v104i0001&article=3_tuolhfmovtip"">Bibliographic Pagef=""http://202.120.13.78/cgi-bin/sciserv.pl?collection=journals&journal=03012115&issue=v104i0001&article=3_tuolhfmovtip&form=pdf&file=file.pdf"">Full Text
  2. Empson, Marianne; Lassere, Marissa; Craig, Jonathan C.; Scott, James R.,""Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trialsf=""#footnote_2"">2""Obstetrics and Gynecology2002pp. 135-144
    f=""http://202.120.13.78/cgi-bin/sciserv.pl?collection=journals&journal=00297844&issue=v99i0001&article=135_rplwaaasrott"">Bibliographic Pagef=""http://202.120.13.78/cgi-bin/sciserv.pl?collection=journals&journal=00297844&issue=v99i0001&article=135_rplwaaasrott&form=pdf&file=file.pdf"">Full Text
  3. Jacobsen, Anne Flem; Qvigstad, Erik; Sandset, Per Morten,""Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy""BJOG: An International Journal of Obstetrics and Gynaecology2003pp. 139-144
    f=""http://202.120.13.78/cgi-bin/sciserv.pl?collection=journals&journal=14700328&issue=v110i0002&article=139_lmwhfttovtip"">Bibliographic Pagef=""http://202.120.13.78/cgi-bin/sciserv.pl?collection=journals&journal=14700328&issue=v110i0002&article=139_lmwhfttovtip&form=pdf&file=file.pdf"">Full Text
  4. Massicotte, Patricia; Julian, Jim A.; Marzinotto, Velma; Gent, Michael; Shields, Karen; Chan, Anthony K.; Szechtman, Barbara; Kohne, Steven; Shepherd, Steven; Bacher, Peter; Andrew, Maureen,""Dose-finding and pharmacokinetic profiles of prophylactic doses of a low molecular weight heparin (reviparin-sodium) in pediatric patients""Thrombosis Research2003pp. 93-99
    f=""http://202.120.13.78/cgi-bin/sciserv.pl?collection=journals&journal=00493848&issue=v109i2-3&article=93_dappopmwhipp"">Bibliographic Pagef=""http://202.120.13.78/cgi-bin/sciserv.pl?collection=journals&journal=00493848&issue=v109i2-3&article=93_dappopmwhipp&form=pdf&file=file.pdf"">Full Text
font>
<font face=""arial"" size=""-1"" color=""black""> Footnotes:
    me=""footnote_1"">
  1. The results of this paper were presented at the International Society of Thrombosis and Hemostasis Meeting in Washington D.C. in August of 1999.

© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

地址:北京市海淀区学院路29号 邮编:100083

电话:办公室:(+86 10)66554848;文献借阅、咨询服务、科技查新:66554700